Idence of 6.1 per 100 person-years) and 60 were in the placebo group (incidence of 5.6 per 100 person-years). There was no significant difference in time to HSV-2 incidence among participants assigned to the FTC/TDF arm compared with those assigned to the placebo arm (HR 1.1, 95 CI: 0.8?.5; P = 0.64; Figure 2). Compared with participants in the placebo arm, there was also no difference in time to
Idence of 6.1 per 100 person-years) and 60 were in the placebo group (incidence of 5.6 per 100 person-years). There was no significant difference in time to HSV-2 incidence among participants assigned to the FTC/TDF arm compared with those assigned to the placebo arm (HR 1.1, 95 CI: 0.8?.5; P = 0.64; Figure 2). Compared with participants in the placebo arm, there was also no difference in time to